Clinical update

Durvalumab: NICE recommends new lung cancer treatment

New drug is 'biggest advance' seen for some time in treating certain lung cancers

New immunotherapy treatment 'biggest advance' seen for some time in treating certain lung cancers

Essential facts

A new lung cancer immunotherapy treatment should be made available to some lung cancer patients in England, according to the National Institute for Health and Care Excellence (NICE).

NICE says durvalumab (Imfinzi) should be given to people with locally advanced unresectable non-small-cell lung cancer who have had platinum-based chemoradiation.

Durvalumab is a PD-L1 inhibitor – it helps the body’s immune system to find and attack cancer cells by blocking the PD-L1 protein that disguises cancer.

What's new?

As part of a clinical trial, people taking the drug went for an average of two years without the disease progressing, compared to around six months for those who did not get it.

NICE believes between 27% and 40%


Want to read more?

Unlock full access to RCNi Plus today

Save over 50% on your first three months:

  • Customisable clinical dashboard featuring 200+ topics
  • Unlimited online access to all 10 RCNi Journals including Cancer Nursing Practice
  • RCNi Learning featuring 180+ RCN accredited learning modules
  • NMC-compliant RCNi Portfolio to build evidence for revalidation
  • Personalised newsletters tailored to your interests

This article is not available as part of an institutional subscription. Why is this?